These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8997465)

  • 21. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Submucous myomas treated with gonadotropin releasing hormone agonist and resulting in vaginal hemorrhage. A case report.
    Thorp JM; Katz VL
    J Reprod Med; 1991 Aug; 36(8):625-6. PubMed ID: 1941808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Abnormal menstrual bleeding].
    Steiner RA; Fink D
    Praxis (Bern 1994); 2002 Nov; 91(46):1967-74. PubMed ID: 12476602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration.
    Caraccio N; Dardano A; Manfredonia F; Manca L; Pasquali L; Iudice A; Murri L; Ferrannini E; Monzani F
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4133-7. PubMed ID: 15811929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
    Somani AK; Swick AR; Cooper KD; McCormick TS
    Arch Dermatol; 2008 Oct; 144(10):1341-9. PubMed ID: 18936398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone replacement therapy: aspects of bleeding problems and compliance.
    Samsioe G
    Int J Fertil Menopausal Stud; 1996; 41(1):11-5. PubMed ID: 8673151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
    Minagar A; Ma W; Zhang X; Wang X; Zhang K; Alexander JS; Gonzalez-Toledo E; Albitar M
    Neurol Res; 2012 Jul; 34(6):611-8. PubMed ID: 22709658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
    Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
    Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe deterioration of newly diagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α for concomitant longstanding multiple sclerosis.
    Diamantopoulos AP; Hetland H; Hansen AE; Myklebust G
    Mod Rheumatol; 2012 Jun; 22(3):474-8. PubMed ID: 21928043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post menopausal bleeding related to estrogen therapy. An increasing problem.
    Copenhaver EH
    Geriatrics; 1968 Nov; 23(11):128-30. PubMed ID: 4301353
    [No Abstract]   [Full Text] [Related]  

  • 37. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
    Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
    Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Complication of pernicious anemia during interferon-β treatment for type C chronic hepatitis].
    Ichihara H; Koh S; Aoyama Y; Kumura T; Ohta T; Furukawa Y; Terada Y; Yamane T; Hino M; Mugitani A
    Rinsho Ketsueki; 2012 Mar; 53(3):352-6. PubMed ID: 22499054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
    Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
    Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.